Skip to main content

Table 4 Factors associated with rapid recovery in patients undergoing sedative bronchoscopy

From: Analgosedation during flexible fiberoptic bronchoscopy: comparing the clinical effectiveness and safety of remifentanil versus midazolam/propofol

 

Univariable analysis

Multivariable analysis

Unadjusted OR (95% CI)

p

Adjusted OR (95% CI)

p

Age, yr

0.98 (0.95–1.01)

0.131

0.97 (0.93–1.001)

0.059

Female

0.71 (0.30–1.71)

0.448

0.53 (0.18–1.54)

0.241

Body mass index, kg/m2

0.93 (0.93–1.11)

0.772

0.92 (0.82–1.04)

0.195

COPD or asthma

0.37 (0.07–2.01)

0.249

0.93(0.11–7.76)

0.946

Chronic heart disease

2.74 (0.76–9.91)

0.123

0.62 (0.09–4.32)

0.628

Indication

 Others

Ref

 

Ref

 

 Lung cancer

0.53 (0.15–1.95)

0.343

0.69 (0.13–3.66)

0.665

 Infection

0.90 (0.31–2.59)

0.841

1.43 (0.40–5.05)

0.581

 Interstitial lung disease

0.98 (0.22–4.28)

0.976

1.72 (0.29–10.06)

0.548

Procedure

 Inspection only

Ref

 

Ref

 

 Inspection with bronchoscopic biopsy

0.92 (0.25–3.39)

0.896

0.27 (0.04–1.64)

0.154

 Inspection with BAL and/or TBLB

0.92 (0.19–4.40)

0.913

0.67 (0.10–4.55)

0.684

Sedative drug

 Midazolam/propofol

Ref

 

Ref

 

 Remifentanyl

7.70 (2.74–21.65)

< 0.001

15.88 (4.14–60.90)

< 0.001

  1. Data are present as a ratio (95% CI)
  2. OR Odds ratio, CI Confidence interval, COPD Chronic obstructive pulmonary disease, BAL Bronchoalveolar lavage, TBLB Transbronchial lung biopsy, Ref Reference